Trial · NCT07153367

Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)

NCT07153367, Phase 2, Recruiting, Centre Hospitalier Intercommunal Creteil

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE). Trials, record NCT07153367. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07153367

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)
NCT number: NCT07153367
Status: Recruiting
Phases: Phase 2
Enrollment: 80 participants, estimated
Lead sponsor: Centre Hospitalier Intercommunal Creteil
Conditions: Infertility, Insemination
Interventions: REKOVELLE (Follitropin Delta)
First posted: 2025-09-04
Last updated: 2026-04-08

Source ClinicalTrials.gov

Registered outcomes38

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage of cycles with two mature follicles (total of two ovaries) at the stage of triggering ovulation	up to 9 months	Percentage of cycles with two mature follicles (total of two ovaries) at the stage of triggering ovulation (follicles diameter ≥14 mm) and no follicles between 10 et 13 mm.
Secondary	Number of follicles ≥14 mm on the day of trigger	Up to Day 15 of the cycle (each cycle is 28 days)	Number of follicles ≥14 mm on the day of trigger ( by cycle)
Secondary	Number of follicles between 10 et 13 mm on the day of trigger	Up to Day 15 of the cycle (each cycle is 28 days)	Number of follicles between 10 et 13 mm on the day of trigger (by cycle)
Secondary	Percentage of cycles with two mature follicles (total of two ovaries) at the stage of triggering ovulation (follicles diameter ≥14 mm) and no follicles between 10 et 13 mm for each cycle and according to dose adjustment	up to 9 months	Percentage of cycles with two mature follicles (total of two ovaries) at the stage of triggering ovulation (follicles diameter ≥14 mm) and no follicles between 10 et 13 mm for each cycle and according to dose adjustment
Secondary	Presence or absence of dose adjustment in subsequent cycles	up to 9 months	Presence or absence of dose adjustment in subsequent cycles
Secondary	E2 level on the day of trigger	Up to Day 15 of the cycle (each cycle is 28 days)	E2 level on the day of trigger (pg/ml)
Secondary	Dose adjustment on subsequent cycle(s) : quantity of mcg	up to 9 months	Dose adjustment on subsequent cycle(s) : quantity of mcg
Secondary	PG level on the day of trigger	Up to Day 15 of the cycle (each cycle is 28 days)	PG level on the day of trigger (ng/ml)
Secondary	LH level on the day of trigger	Up to Day 15 of the cycle (each cycle is 28 days)	LH level on the day of trigger (UI/L)
Secondary	Frequency of spontaneous LH surge by cycle , at the end of stimulation	up to 9 months	Frequency of spontaneous LH surge by cycle , at the end of stimulation (last day of stimulation)

1 to 10 of 38Source ClinicalTrials.gov

See all 38 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07153367

GET https://conductscience.org/api/trials/v1/NCT07153367/registered?page=2

API reference For AI assistants